New hope for cancer patients: drug may prevent weight loss during treatment
NCT ID NCT06995508
First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This study tests whether adding olanzapine to standard nausea care helps head and neck cancer patients maintain their appetite and weight during chemoradiation. About 66 adults will be randomly assigned to receive either olanzapine plus standard care or standard care alone. The main goal is to see if olanzapine reduces weight loss and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.